Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Professor Adrian Hill elected as Fellow of the Royal Society

Professor Adrian Hill is elected as Fellow of the Royal Society for his world-leading work in the design and development of new vaccines for globally important infectious diseases. He founded and directs the Jenner Institute at Oxford University.

Malaria vaccine becomes first to achieve WHO-specified 75% efficacy goal

Researchers from the University of Oxford and their partners have today reported findings from a Phase IIb trial of a candidate malaria vaccine, R21/Matrix-M, which demonstrated high-level efficacy of 77% over 12-months of follow-up.

Significant reductions in COVID-19 infections found after single dose of Oxford-AstraZeneca and Pfizer-BioNTech vaccine

COVID-19 infections fell significantly – by 65% percent - after a first dose of the Oxford-AstraZeneca or Pfizer-BioNTech vaccines in this large community surveillance study.

Alternating vaccines trial expands to include two additional vaccines

Researchers running the Com-Cov study, launched in February to investigate alternating doses of the Oxford-AstraZeneca vaccine and the Pfizer vaccine, have today announced that the programme will be extended to include the Moderna and Novavax vaccines in a new study.

UK and EU regulators conclude benefits of vaccination continue to outweigh the risks

Today, the medical regulators in the UK and Europe have announced their conclusions from their reviews of very rare cases of unusual blood clots in people who have received the Oxford-AstraZeneca coronavirus vaccine. Both the UK's Medicines and Healthcare products Regulatory Agency (MHRA) and the EU's European Medicines Agency have concluded that whilst there was a possible link from these very rare blood clots to the vaccine, the benefits of vaccination continue to outweigh the risks in all age groups, and have requested the product information is updated to mitigate further risks.

AstraZeneca publish primary analysis from US trial of coronavirus vaccine

Our partners AstraZeneca have today announced the high-level results from the primary analysis of their Phase III trial of the ChAdOx1 nCoV-19 coronavirus vaccine in the US. They confirm that the vaccine efficacy is consistent with the interim analysis results announced on Monday 22 March 2021.

Marking 100 years of the tuberculosis BCG vaccine

The VALIDATE Network, a community of over 400 researchers based in more than 200 research institutions in 63 countries, will today launch the “BCG100 Programme” marking the centenary of the Bacille Calmette-Guérin Vaccine for tuberculosis. BCG100 officially launches with the ‘BCG Then and Now’ online lecture by Professor Helen McShane, VALIDATE Network Director and Jenner Investigator and Professor Paul Fine, London School of Hygiene and Tropical Medicine. Taking place at 6pm GMT, 24 March 2021, the talk will cover the initial development of the vaccine, moving through to the modern-day challenges in the fight against TB and the future challenges researchers face in replacing the enduring BCG vaccine.

USA, Chile and Peru interim trial data show Oxford-AstraZeneca vaccine is safe and highly effective

A Phase III study of the Oxford-AstraZeneca coronavirus vaccine conducted by AstraZeneca plc in the USA, Chile and Peru has shown that vaccine is safe and highly effective, adding to previous trial data from the United Kingdom, Brazil and South Africa, as well as real-world impact data from the United Kingdom.

Existing vaccines may protect against the Brazilian coronavirus variant

Scientists at the University of Oxford have released pre-print data measuring the level of antibodies that can neutralise – or stop infection from – variants that are circulating in South Africa, Brazil and elsewhere. These data suggest that natural- and vaccine-induced antibodies can still neutralise these variants, but at lower levels. Importantly, the P1 ‘Brazilian’ strain may be less resistant to these antibodies than first feared.

Oxford vaccine creator Professor Sarah Gilbert awarded RSA Albert Medal

Professor Sarah Gilbert has been awarded the Royal Society for Arts, Manufactures and Commerce’ (RSA) Albert Medal for her work on the Oxford vaccine. The lead researcher on the Oxford vaccine team, Professor Gilbert is Professor of Vaccinology in the Nuffield Department of Medicine at the University of Oxford. She is the Oxford Project Leader for ChAdOx1 nCoV-19, a vaccine against the novel coronavirus, SARSCoV-2, with approval for use in many countries around the world.

New data show vaccines reduce severe COVID-19 in older adults

Today Public Health England (PHE) has submitted a pre-print of a real-world study that shows that the Oxford / AstraZeneca and Pfizer vaccines are both highly effective in reducing COVID-19 infections among older people aged 70 years and over. Both vaccines had about 60% protection against symptomatic infection in this age group.

Coronavirus vaccination linked to substantial reduction in hospitalisation, real-world data suggests

The first study to describe the effects in real-world communities of the Oxford coronavirus vaccine has been reported in a pre-print publication today, showing a clear reduction in the risk of hospitalisation from COVID-19 amongst those who have received the vaccine.

Oxford University extends COVID-19 vaccine study to children

The University of Oxford, together with three partner sites in London, Southampton and Bristol, is to launch the first study to assess the safety and immune responses in children and young adults of the ChAdOx1 nCoV-19 coronavirus vaccine.

World Health Organization experts provide guidance on use of the Oxford vaccine

WHO SAGE says Oxford's vaccine is safe and likely to be efficacious in older adults, and recommends its use in this age group. The World Health Organization (WHO) Strategic Advisory Group of Experts (SAGE) yesterday produced guidelines for the emergency use of the ChAdOx1 nCoV-19 coronavirus vaccine developed by the University of Oxford with its partner AstraZeneca.

Oxford coronavirus vaccine shows sustained protection of 76% during the 3-month interval until the second dose

Analyses reveal single standard dose efficacy from day 22 to day 90 post vaccination of 76% with protection not falling in this three-month period. After the second dose vaccine efficacy from two standard doses is 82.4% with the 3-month interval being used in the UK (82.4% effective, with a 95% confidence interval of 62.7% - 91.7% at 12+ weeks). Data supports the 4-12 week prime-boost dosing interval recommended by many global regulators. Analyses of PCR positive swabs in UK population suggests vaccine may have substantial effect on transmission of the virus with 67% reduction in positive swabs among those vaccinated.

Oxford leads first trial investigating dosing with alternating vaccines

The University of Oxford is to lead the first trial to explore alternating different COVID-19 vaccines, to explore the potential for flexibility in delivery and look for clues as to how to increase the breadth of protection against new virus strains.

Oxford coronavirus vaccine shows sustained protection of 76% during the 3-month interval until the second dose

Researchers at the University of Oxford have today published in Preprints with The Lancet an analysis of further data from the ongoing trials of the vaccine. In this, they reveal that the vaccine efficacy is higher at longer prime-boost intervals, and that a single dose of the vaccine is 76% effective from 22- to up to 90-days post vaccination.

Oxford University vaccine developer joins day of vaccinations at the Kassam Stadium

Today, Andrew Pollard, Professor of Pediatric Infection and Immunity at the University of Oxford, and chief investigator of the trials of the ChAdOx1 nCoV-19 coronavirus vaccine, volunteered his time to help deliver live-saving Covid vaccinations at the newly opened NHS Vaccine Centre at the Kassam Stadium, Oxford.

UK National Health Service begins rollout of Oxford coronavirus vaccine

At 7.30 am today, dialysis patient Brian Pinker became the very first person to be vaccinated as part of the UK’s rollout of the Oxford / AstraZeneca coronavirus vaccine, ChAdOx1 nCoV-19, with patients at the Oxford University NHS Hospitals Trust becoming the first to receive this life-saving vaccine.

University of Oxford welcomes regulatory authorisation of coronavirus vaccine

The University of Oxford welcomes the news that the UK Government has today accepted the recommendation from the Medicines and Healthcare products Regulatory Agency (MHRA) to authorise the emergency use of the ChAdOx1 nCoV-19 coronavirus vaccine in the UK.

Load More